Sign Up
bf/AMEX:CLDI_icon.jpeg

COM:CALIDIBIO

Calidi Biotherapeutics

  • Stock

USD

Last Close

2.15

22/11 21:00

Market Cap

21.63M

Beta: -

Volume Today

1.48M

Avg: -

OverviewAnalysisMetricsFinancialsFilingsAPIChartData
Income StatementBalance SheetCash FlowKey MetricsRatios
Quarterly
Yearly

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '21
Dec '22
Dec '23
average inventory
average payables
442.92K
-
1.45M
226.81%
2.57M
77.82%
average receivables
680K
-
book value per share
74.89
-
-48.02
164.11%
-0.49
98.98%
capex per share
0.07
-
0.50
602.33%
0.03
93.12%
capex to depreciation
1.35
-
1.65
22.26%
0.47
71.71%
capex to operating cash flow
-0.19
-
-0.03
82.97%
-0.02
33.06%
capex to revenue
0.46
-
9.51
1,973.05%
cash per share
0.37
-
0.55
50.15%
0.12
78.14%
days of inventory on hand
days payables outstanding
247.89
-
3.03K
1,120.42%
836.07
72.36%
days sales outstanding
debt to assets
0.02
-
2.09
9,244.80%
0.29
86.30%
debt to equity
0.02
-
-0.13
652.07%
-0.35
162.08%
dividend yield
earnings yield
0.01
-
-0.29
2,548.07%
-0.12
59.13%
enterprise value
286.16M
-
92.01M
67.85%
248.36M
169.92%
enterprise value over ebitda
-160.61
-
-3.68
97.71%
-9.00
144.63%
ev to operating cash flow
-264.25
-
-6.96
97.36%
-9.20
32.18%
ev to sales
637.32
-
2.04K
220.83%
free cash flow per share
-0.45
-
-16.04
3,477.87%
-1.63
89.82%
free cash flow yield
-0.00
-
-0.16
3,351.22%
-0.11
28.12%
graham net net
-5.35
-
-50.52
843.77%
-0.90
98.22%
graham number
44.55
-
179.72
303.38%
4.36
97.58%
income quality
-0.32
-
0.52
262.53%
0.92
77.72%
intangibles to total assets
0
-
0
0
interest coverage
-2.90
-
-146.38
4,944.46%
-27.12
81.47%
interest debt per share
2.02
-
6.56
225.67%
0.23
96.45%
inventory turnover
invested capital
1.66M
-
-41.12M
2,580.55%
-586K
98.57%
market cap
282.04M
-
86.50M
69.33%
243.17M
181.14%
net current asset value
-14.97M
-
-42.65M
184.95%
-13.95M
67.29%
net debt to ebitda
-2.31
-
-0.22
90.45%
-0.19
14.77%
net income per share
1.18
-
-29.90
2,637.91%
-1.73
94.21%
operating cash flow per share
-0.38
-
-15.54
4,024.89%
-1.60
89.72%
payables turnover
1.47
-
0.12
91.81%
0.44
261.84%
receivables turnover
research and ddevelopement to revenue
10.41
-
161.27
1,449.18%
return on tangible assets
0.01
-
-9.79
67,103.26%
-2.92
70.22%
revenue per share
0.16
-
0.05
66.12%
roe
0.02
-
0.62
3,858.38%
3.55
469.82%
roic
-0.01
-
0.65
8,212.15%
5.40
727.09%
sales general and administrative to revenue
13.73
-
353.38
2,474.50%
shareholders equity per share
74.89
-
-48.02
164.11%
-0.49
98.98%
stock based compensation to revenue
2.96
-
136.51
4,518.95%
tangible asset value
215.32M
-
-40.84M
118.97%
-8.23M
79.84%
tangible book value per share
74.89
-
-48.02
164.11%
-0.49
98.98%
working capital
1.07M
-
-42.20M
4,034.73%
-5.93M
85.95%

All numbers in USD (except ratios and percentages)